That sounds pretty disappointing for the company and investors, NO? Weren't they counting very much on this study for their acceptance in the NO PAIN ACT? If THIS study is not used, what is their backup plan for benefiting from that NO PAIN ACT? With those results, and if that was their only proof of qualifying, it looks like they will not be rewarded by that NO PAIN ACT. And if those results are true and the trial is done, why haven't the stockholders been informed of those results? Isn't this information important enough, thus required to be reported to the stockholders of a publicly traded company? I am sure that the CEO is very reluctant to report those findings if true.
Bad enough if this trial did not show statistical significant difference of reduction of pain, but to be be LESS effective is very troublesome and concerning, NO?
Market Data 
Markets 
AI
